Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q1 2024 · 10-Q
Revenue$8.50M$8.50M−7.9% vs Q1 2023 Net Income-$1.95M-$1.95MN/M vs Q1 2023 EPS Diluted-$0.14-$0.14N/M vs Q1 2023 Operating Income-$1,869,250N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,178,268N/M Margins · derivedOperating margin-22.0%−5.4 pt vs Q1 2023
Net margin-22.9%−25.0 pt vs Q1 2023
ended Mar 31, 2024 · filed May 10, 2024 · 40 d after period end